Clinical Trial Detail

NCT ID NCT02543255
Title Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

prostate adenocarcinoma

Therapies

Cabazitaxel

Abiraterone + Leuprolide + Prednisone

Pegfilgrastim

Age Groups: adult

No variant requirements are available.